Managing Adverse Effects

Active Resources: 6

Slide Sets

COVID-19 Update for People with HIV

4/9/2020

Antiretroviral Guidelines

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

12/18/2019

Image Library

AIDSinfo Illustrated Glossary

2/20/2019 (reviewed: 2/20/2019)

Online Training

AETC National HIV Curriculum

10/20/2017

Patient Information

HIV Medicines and Side Effects

10/9/2017

Self-Study Materials

Update from the 18th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

2/1/2017

Archive Resources: 2

Videos

Medication-Related Osteonecrosis of the Jaw

4/1/2015

Pocket Guides

Pharmacy Recommendations for HIV and Aging

4/1/2015

Articles: 3

Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

August 31, 2017
Laura Cheever, MD, ScM , HRSA HIV/AIDS Bureau
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
Switching from TDF/FTC to TAF/FTC

March 18, 2016
Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
Cobicistat and Stribild Use in Patients with Renal Insufficiency

October 15, 2013
Ian R. McNicholl, PharmD, BCPS (AQ-Infectious Diseases), AAHIVE
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate...